|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. 2003. Progress in cancer screening practices in the United States: Results from the 2000 National Health Interview Survey. Cancer 97(6):1528-1540. Takahashi H, Echizen H. 2003. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. The Pharmacogenomics Journal 3(4):202-214. UK Department of Health. 2002. Drug Treatment for Multiple Sclerosis (Beta-Interferons and Glatiramer Acetate)—Risk Sharing Scheme. [Online]. Available: http://www.dh.gov.uk/PolicyAndGuidance/OrganisationPolicy/PrimaryCare/PrimaryCareTrusts/PrimaryCareTrustsArticle/fs/en?CONTENT_ID=4000556&chk=nvlrjJ [accessed September 2006]. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. 2002. A gene-expression signature as a predictor of survival in breast cancer. New England Journal of Medicine 347(25):1999-2009. Weinstein S, Obuchowski NA, Lieber ML. 2005. Clinical evaluation of diagnostic tests. American Journal of Roentgenology 184(1):14-19.
|
|
|||||||||||||||
